Accesswire

VILNIUS, LITHUANIA / ACCESSWIRE / May 13, 2024 / Mobile application developer Kilo Payments, Inc. has unveiled a new screen time management app for iOS called DopaFast aimed at addressing smartphone addiction and promoting healthier screen habits. Unlike its counterparts, DopaFast stands out for its innovative approach to screen blocking, making it significantly more challenging to bypass.

DopaFast operates by allowing users to select which distracting apps they want to... (continue reading...)

Seamless Omnichannel Integration Empowers B2B Organizations

BOCA RATON, FL / ACCESSWIRE / May 13, 2024 / INFUSE, the top global B2B demand performance partner, has announced a new partnership with 6sense�, the leading platform that revolutionizes the way B2B organizations create, manage, and convert pipeline to revenue. This strategic partnership marks a significant milestone in delivering unparalleled demand activation capabilities to clients of both 6sense and INFUSE.

Transaction in Own Shares

LONDON, UK / ACCESSWIRE / May 13, 2024 / Ecora Resources PLC (LSE:ECOR)(TSX:ECOR) announces that on 10 May 2024, it purchased 100,000 ordinary shares of 2p each in the Company (the "Shares") on the London Stock Exchange through Peel Hunt LLP, in accordance with the terms of its share buyback programme announced on 27 March 2024 (the "Programme"). The shares acquired will be held in treasury.

Date of purchase:

10 May 2024

Aggregate number of... (continue reading...)

STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) On May 13th, PMD Device Solutions (PMDS) signed a Letter of Intent with Red Line Microconsult AB's CEO, Magnus Sorlander, for a 2 MSEK annual license fee and a royalty on all sales.

PMDS and Magnus Sorlander, the founder of Coala-Life and CEO of Red Line Microconsult AB, have signed a Letter of Intent to develop and sell the monitoring technology, Coala-Life Monitor, within Europe.... (continue reading...)

STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company has received preclinical data for NeuroRestore in inflammation, with relevance to Alzheimer's disease, and submitted a new patent application for NeuroRestore ACD856, which... (continue reading...)